BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33993837)

  • 1. 3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance.
    Alhallak K; de la Puente P; Jeske A; Sun J; Muz B; Rettig MP; Sahin I; Weisberg EL; Griffin JD; Reagan JL; DiPersio JF; Azab AK
    Leuk Lymphoma; 2021 Oct; 62(10):2457-2465. PubMed ID: 33993837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three hematologic malignancies in the same patient: chronic lymphocytic leukemia, followed by chronic myeloid leukemia and acute myeloid leukemia.
    Fattizzo B; Radice T; Cattaneo D; Pomati M; Barcellini W; Iurlo A
    Clin Lab; 2014; 60(11):1929-32. PubMed ID: 25648037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.
    Engelhardt M; Mackenzie K; Drullinsky P; Silver RT; Moore MA
    Cancer Res; 2000 Feb; 60(3):610-7. PubMed ID: 10676644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of cyclins D1, D2, and D3 and Ki-67 in Leukemia.
    Jaroslav P; Martina H; Jirí S; Hana K; Petr S; Tomás K; Julius M; Cedrik H
    Leuk Lymphoma; 2005 Nov; 46(11):1605-1612. PubMed ID: 16334487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Myelogenous Leukemia Diagnosed in the Setting of Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    Viswanathan K; Roboz G; Chadburn A; Mathew S
    Int J Surg Pathol; 2020 Apr; 28(2):216-224. PubMed ID: 31544558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A case of chronic myeloid leukemia occurring during treatment for chronic lymphocytic leukemia].
    Hattori H; Kuwayama M; Kotake T; Karasuno T
    Gan To Kagaku Ryoho; 2011 Feb; 38(2):333-6. PubMed ID: 21368508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Argyrophilic nucleolar organizer regions (AgNORs) in relation to p53 and bcl-2 protein expression in leukemia patients.
    Klobusická M; Kusenda J; Babusíková O
    Neoplasma; 2003; 50(6):408-15. PubMed ID: 14689061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia.
    Yamamoto-Sugitani M; Kuroda J; Ashihara E; Nagoshi H; Kobayashi T; Matsumoto Y; Sasaki N; Shimura Y; Kiyota M; Nakayama R; Akaji K; Taki T; Uoshima N; Kobayashi Y; Horiike S; Maekawa T; Taniwaki M
    Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17468-73. PubMed ID: 21987825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Hydroxypropyl-β-Cyclodextrin Acts as a Novel Anticancer Agent.
    Yokoo M; Kubota Y; Motoyama K; Higashi T; Taniyoshi M; Tokumaru H; Nishiyama R; Tabe Y; Mochinaga S; Sato A; Sueoka-Aragane N; Sueoka E; Arima H; Irie T; Kimura S
    PLoS One; 2015; 10(11):e0141946. PubMed ID: 26535909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
    Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
    Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
    J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib-responsive chronic lymphocytic leukemia in a patient treated for coexisting chronic myeloid leukemia.
    Nagao T; Takahashi N; Kameoka Y; Noguchi S; Shinohara Y; Ohyagi H; Kume M; Sawada K
    Intern Med; 2013; 52(22):2567-71. PubMed ID: 24240798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro drug resistance in B cell chronic lymphocytic leukemia: a comparison with acute myelocytic and acute lymphocytic leukemia.
    Aleskog A; Larsson R; Höglund M; Kristensen J; Nygren P; Lindhagen E
    Anticancer Drugs; 2005 Mar; 16(3):277-83. PubMed ID: 15711179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active Hexose-Correlated Compound Shows Direct and Indirect Effects against Chronic Lymphocytic Leukemia.
    Merchand-Reyes G; Santhanam R; Valencia-Pena ML; Kumar K; Mo X; Belay T; Woyach JA; Mundy-Bosse B; Tridandapani S; Butchar JP
    Nutrients; 2023 Dec; 15(24):. PubMed ID: 38140397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
    Weisberg E; Banerji L; Wright RD; Barrett R; Ray A; Moreno D; Catley L; Jiang J; Hall-Meyers E; Sauveur-Michel M; Stone R; Galinsky I; Fox E; Kung AL; Griffin JD
    Blood; 2008 Apr; 111(7):3723-34. PubMed ID: 18184863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
    Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation analysis of the FAS and TNFR apoptotic cascade genes in hematological malignancies.
    Rozenfeld-Granot G; Toren A; Amariglio N; Brok-Simoni F; Rechavi G
    Exp Hematol; 2001 Feb; 29(2):228-33. PubMed ID: 11166462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression pattern and prognostic implication of SALL4 gene in myeloid leukemias: a case-control study.
    Farawela HM; Zawam HM; Al-Wakeel HA; El-Nagdy MH; El-Refaey FA; Abdel-Rahman HA
    Scand J Clin Lab Invest; 2019; 79(1-2):65-70. PubMed ID: 30638095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
    Shi X; Chen X; Li X; Lan X; Zhao C; Liu S; Huang H; Liu N; Liao S; Song W; Zhou P; Wang S; Xu L; Wang X; Dou QP; Liu J
    Clin Cancer Res; 2014 Jan; 20(1):151-63. PubMed ID: 24334603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic and therapeutic potential of HO-1 in leukemia and MDS.
    Sadeghi M; Fathi M; Gholizadeh Navashenaq J; Mohammadi H; Yousefi M; Hojjat-Farsangi M; Namdar A; Movasaghpour Akbari AA; Jadidi-Niaragh F
    Cell Commun Signal; 2023 Mar; 21(1):57. PubMed ID: 36915102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.